Chung-Wu Lin

Chung-Wu Lin

Auto-generated profile, based on publicly available information

Chung-Wu Lin

Department of Pathology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2009 in Nature Cell Biology
Verified
Journal Article
Closed access
SWShu-Ping Wang
Shu-Ping Wang
WWWen-Lung Wang
Wen-Lung Wang
YCYih-Leong Chang
Yih-Leong Chang
YCYih-Leong Chang
Yih-Leong Chang
YCYu-Chih Chao
Yu-Chih Chao
PYPan-Chyr Yang
Pan-Chyr Yang

1 October 2010 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
TLTzu-Pin Lu
Tzu-Pin Lu
MTMong-Hsun Tsai
Mong-Hsun Tsai
JLJang-Ming Lee
Jang-Ming Lee
CHChung-Ping Hsu
Chung-Ping Hsu
PCPei-Chun Chen
Pei-Chun Chen
ECEric Y. Chuang
Eric Y. Chuang
Background: Although cigarette smoking is the major risk factor for lung cancer, only 7% of female lung cancer patients in Taiwan have a history of smoking. The genetic mechanisms of carcinogenesis in nonsmokers are unclear, but semaphorins have been suggested to play a role as lung tumor suppressors. This report is a comprehensive analysis of the molecular signature of nonsmoking female lung cancer patients in Taiwan, with a particular focus on the semaphorin gene family.

15 January 2009 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
YCYu-Chih Chao
Yu-Chih Chao
SPSZU-HUA PAN
SZU-HUA PAN
SYShuenn-Chen Yang
Shuenn-Chen Yang
SYSung-Liang Yu
Sung-Liang Yu
TCTing-Fang Che
Ting-Fang Che
PYPan-Chyr Yang
Pan-Chyr Yang
Rationale: Claudin (CLDN)-1, a key component of tight junction complexes, was down-regulated in human lung adenocarcinomas. Objectives: To investigate the clinical significance of CLDN1 expression in patients with lung adenocarcinoma and its role in cancer invasion and metastasis. Methods: We examined the CLDN1 mRNA expression in tumor specimens from 64 patients with lung adenocarcinoma and protein expression by immunohistochemistry in an independent cohort of 67 patients with lung adenocarcinoma. CLDN1 functions in cancer cell migration, invasion, and metastatic colonization were studied by overexpression and knockdown of CLDN1. Affymetrix microarrays were performed to identify gene expression changes associated with CLDN1 overexpression. Measurements and Main Results: We found that low-CLDN1 mRNA expression had shorter overall survival (P = 0.027, log-rank test) in 64 patients with lung adenocarcinoma, and we confirmed by immunohistochemistry that low CLDN1 expression had shorter overall survival (P = 0.024, log-rank test) in an independent cohort of 67 patients with lung adenocarcinoma. Overexpression of CLDN1 inhibited cancer cell dissociation in time-lapse imaging of wound healing, and suppressed cancer cell migration, invasion, and metastasis. Knockdown CLDN1 expression increased cancer cell invasive and metastatic abilities. Affymetrix microarrays identified a panel of genes altered by CLDN1 overexpression. CLDN1 increased expressions of cancer invasion/metastasis suppressors (e.g., connective tissue growth factor [CTGF], thrombospondin 1 [THBS1], deleted in liver cancer 1 [DLC1], occludin [OCLN], zona occludens 1 [ZO-1]) and suppressed expressions of invasion/metastasis enhancers (e.g., secreted phosphoprotein 1 [SPP1], cut-like homeobox 1 [CUTL1], transforming growth factor alpha [TGF-α], solute carrier family 2 [faciliated glucose transporter] member 3 [SLC2A3], placental growth factor [PGF]), supporting a role for CLDN1 as an invasion and metastasis suppressor. Conclusions: CLDN1 is a cancer invasion/metastasis suppressor. CLDN1 is also a useful prognostic predictor and potential drug treatment target for patients with lung adenocarcinoma.

24 May 2012 in Blood
Verified
Journal Article
Closed access
PDF file
SKSung-Hsin Kuo
Sung-Hsin Kuo
KYKun-Huei Yeh
Kun-Huei Yeh
MWMing-Shiang Wu
Ming-Shiang Wu
CLChung-Wu Lin
Chung-Wu Lin
PHPing-I Hsu
Ping-I Hsu
LCLi-Tzong Chen
Li-Tzong Chen
An explorative study evaluates the efficacy of Helicobacter pylori (HP) eradication (HPE) therapy on early-stage gastric diffuse large B-cell lymphomas (DLBCLs) without features of mucosa-associated lymphoid tissue (MALT), the pure (de novo) DLBCLs, in comparison with its efficacy on high-grade transformed gastric MALT lymphomas, the DLBCL(MALT). In total, 50 patients of stage IE/IIE1 HP-positive gastric DLBCLs with frontline HPE treatment were included. HP infection was successfully eradicated in 100% (16/16) of the pure (de novo) DLBCL patients and 94.1% (32/34) of the DLBCL(MALT) patients. In total, 68.8% (11/16) of pure (de novo) DLBCL patients and 56.3% (18/32) of DLBCL(MALT) patients achieved complete pathologic remission (pCR) after HPE therapy. The median time to pCR was 2.1 months (95% confidence interval, 0.6%-3.7%) for pure (de novo) DLBCLs and 5.0 months (95% confidence interval, 2.8%-7.5%; P = .024) for DLBCL(MALT). At a median follow-up of 7.7 years, all patients with pCR after HPE therapy were alive and free of lymphomas, except for one patient with pure (de novo) DLBCL who died of lung cancer. Similar to DLBCL(MALT), a substantial portion of early-stage HP-positive gastric pure (de novo) DLBCLs remains HP-dependent and responds to antibiotic treatment. Prospective studies to validate the findings are warranted.

1 June 2011 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Closed access
YTYu-Tzu Tseng
Yu-Tzu Tseng
WSWang-Huei Sheng
Wang-Huei Sheng
BLBo-Han Lin
Bo-Han Lin
CLChung-Wu Lin
Chung-Wu Lin
Jann-Yuan WangJann-Yuan Wang
Jann-Yuan Wang
SCShan-Chwen Chang
Shan-Chwen Chang

21 June 2006 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
MTMeng-Feng Tsai
Meng-Feng Tsai
CWChi-Chung Wang
Chi-Chung Wang
GCGee-Chen Chang
Gee-Chen Chang
CCChih-Yi Chen
Chih-Yi Chen
HCHsuan-Yu Chen
Hsuan-Yu Chen
PYPan-Chyr Yang
Pan-Chyr Yang
Background: We previously identified DnaJ-like heat shock protein (HLJ1) as a gene associated with tumor invasion. Here, we investigated the clinical significance of HLJ1 expression in non–small-cell lung cancer (NSCLC) patients and its role in cancer progression. Methods: We induced HLJ1 overexpression or knockdown in human lung adenocarcinoma CL1–5 cells and analyzed cell proliferation, anchorage-independent growth, in vivo tumorigenesis, cell motility, invasion, and cell cycle progression. Expression of genes that act downstream of HLJ1 was examined by DNA microarray analysis, pathway analysis, and western blotting. We measured HLJ1 expression in tumors and adjacent normal tissues of 71 NSCLC patients by quantitative reverse transcription–polymerase chain reaction. Associations between HLJ1 expression and disease-free and overall survival were determined using the log-rank test and multivariable Cox proportional hazards regression analysis. Validation was performed in an independent cohort of 56 NSCLC patients. Loss of heterozygosity (LOH) mapping of the HLJ1 locus was analyzed in 48 paired microdissected NSCLC tumors. All statistical tests were two-sided. Results: HLJ1 expression inhibited lung cancer cell proliferation, anchorage-independent growth, tumorigenesis, cell motility, and invasion, and slowed cell cycle progression through a novel STAT1/P21 WAF1 pathway that is independent of P53 and interferon. HLJ1 expression was lower in tumors than in adjacent normal tissue in 55 of 71 patients studied. NSCLC patients with high HLJI expressing tumors had reduced cancer recurrence (hazard ratio [HR] = 0.47; 95% confidence interval [CI] = 0.23 to 0.93; P = .03) and longer overall survival (HR = 0.38; 95% CI = 0.16 to 0.89; P = .03) than those with low-expressing tumors. Validation in the independent patient cohort confirmed the association between HLJ1 expression and patient outcome. LOH mapping revealed high frequencies (66.7% and 70.8%) of allelic loss and microsatellite instability (87.5% and 95.2%) of the HLJ1 locus at chromosome 1p31.1. Conclusions: HLJ1 is a novel tumor suppressor in NSCLC, and high HLJ1 expression is associated with reduced cancer recurrence and prolonged survival of NSCLC patients.